Clinical trial data: Adults: A study with Fluarix Tetra in adults has evaluated the incidence of adverse reactions in subjects ≥18 years who received one dose of Fluarix Tetra (N=3,036) or Fluarix (N=1,010).
The following adverse reactions per dose have been reported: (See Table 4.)

Children aged 6 months to <18 years: Two clinical studies evaluated the reactogenicity and safety of Fluarix Tetra in children who received at least one dose of Fluarix Tetra or a control vaccine.
One study enrolled children 3 to <18 years of age who received Fluarix Tetra (N=915) or Fluarix (N=912). The second study enrolled children 6 to <36 months of age who received Fluarix Tetra (N=6,006) or a non-influenza vaccine control (N=6,012) (see Pharmacology: Pharmacodynamics under Actions).
The following adverse reactions per dose have been reported: (See Table 5.)

Post-marketing data: The following adverse reactions have been observed for Fluarix and/or Fluarix Tetra during post-marketing surveillance.1 (See Table 6).

View ADR Reporting Link